Skip to main content
. 2021 Sep 29;22(19):10557. doi: 10.3390/ijms221910557

Figure 1.

Figure 1

Metformin in combination with olaparib decreased cell viability more effectively than each single agent. (A,B) Cell viability after treatment for 24–72 h with olaparib (10–80 µM) and metformin (10–80 mM) in OV-90 and SKOV-3 cells assessed by the MTT assay. (C) The combination effect of olaparib (10–80 µM) and metformin (10–80 mM) was evaluated by the MTT assay after treatment for 24 h. (D) Drug interaction analysis based on the MTT assay after treatment for 24 h. In both cell lines, the combination of O (20 µM) + M (20 mM) showed a synergistic effect (SKOV-3, CDI = 0.74; OV-90 CDI = 0.94). (E) The effect of combination treatment with olaparib (20 µM) and metformin (20 mM) evaluated by the MTT assay after treatment for 48–72 h. (F) Drug interaction analysis based on the MTT assay CDI value for combination of O (20 µM) + M (20 mM) after treatment for 48 h (SKOV-3, CDI = 0.82; OV-90, CDI = 0.95) and for 72 h (SKOV-3, CDI = 0.69; OV-90, CDI = 0.81). Data represent the mean ± SD of three biologic assays. * p < 0.05 for olaparib, metformin, or a combination of both drugs vs. control cells; # p < 0.05 for olaparib vs. combination (O + M); + p < 0.05 for metformin vs. combination (O + M).